Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
Agreement further expands Aptar Pharma’s leading respiratory portfolio
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The recent inspection covered both cGMP and PAI processes
Ami informs that PMDA Japan has issued Inspection Result Report declaring the Sachin facility as a Good Manufacturing Practices (GMP) compliant.
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Subscribe To Our Newsletter & Stay Updated